financetom
Business
financetom
/
Business
/
AppLovin to Sustain 'Phenomenal' Growth, Meet Second-Quarter Estimates, Wedbush Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AppLovin to Sustain 'Phenomenal' Growth, Meet Second-Quarter Estimates, Wedbush Says
Jul 28, 2025 8:12 AM

10:59 AM EDT, 07/28/2025 (MT Newswires) -- AppLovin's ( APP ) "phenomenal" growth is expected to continue, with the mobile technology provider seen largely meeting consensus estimates for the second quarter, Wedbush Securities said in a Monday note.

AppLovin ( APP ), which enables mobile app developers to market and monetize their content through its software platform solutions, is scheduled to release financial results on Aug. 6.

Wedbush expects revenue of $1.23 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1 billion, compared with the consensus estimates of $1.22 billion and $997 million, respectively.

"We expect AppLovin's ( APP ) phenomenal growth to continue," according to Wedbush analysts, including Alicia Reese. "The company should seek ongoing mobile advertising share gains from an uptick in 'user acquisition' spending.

"UA spend on mobile games totals over $30 billion annually across all advertising platforms, and the share spent on third-party mobile games has nearly tripled over the last few years to roughly $15 billion."

Reese expect sequential top-line growth for the software platform segment of 5.7% in the second quarter. AppLovin ( APP ) is expected to issue a sequential growth guidance of 5% for the division, in line with Wedbush' and consensus estimates, according to Reese.

"We don't expect AppLovin ( APP ) to break out revenue from its e-commerce business until it is able/willing to expand its offering to small and mid-size businesses," Reese said. "Our estimates no longer includes revenue from the apps business, as that now shifts to discontinued operations."

Wedbush reiterated its outperform rating on the stock and a $620 price target.

Price: 364.70, Change: +0.56, Percent Change: +0.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Northern Trust Selected by Osmosis Investment Management NL for Middle Office Support
Northern Trust Selected by Osmosis Investment Management NL for Middle Office Support
Nov 17, 2025
08:32 AM EST, 11/17/2025 (MT Newswires) -- Northern Trust ( NTRS ) said Monday it has been selected by Osmosis Investment Management NL to offer middle office support including investment operations outsourcing, collateral management and currency management. Financial terms were not disclosed. Osmosis NL is a Netherlands-based fixed income asset manager. ...
VOC Partners Launches Self-Storage Investment Platform and Exclusive Partnership with Budget Store & Lock
VOC Partners Launches Self-Storage Investment Platform and Exclusive Partnership with Budget Store & Lock
Nov 17, 2025
LEHIGH VALLEY, Pa., Nov. 17, 2025 /PRNewswire/ -- VOC Partners, LLC, a real estate investment firm specializing in data-driven self-storage projects, today announced the official launch of its Self-Storage Investment Platform (SIP) – an institutional framework designed to acquire, develop, and operate high-performing self-storage assets across the Mid-Atlantic region. The firm also introduced its initial SIP Portfolio, representing the first group...
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
Merck expects over $5 billion commercial opportunity from Cidara's flu drug
Nov 17, 2025
Nov 17 (Reuters) - Merck ( MRK ) said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' ( CDTX ) experimental flu drug. The drugmaker struck a deal worth nearly $9.2 billion last week to acquire Cidara to gain access to the long-acting antiviral drug, CD388, currently in late-stage trial. ...
ITT Completes Second Phase of $25 Million Expansion of Saudi Arabia Manufacturing Facility
ITT Completes Second Phase of $25 Million Expansion of Saudi Arabia Manufacturing Facility
Nov 17, 2025
08:35 AM EST, 11/17/2025 (MT Newswires) -- ITT (ITT) said Monday that it has completed the second phase of a planned $25 million expansion of its Industrial Process manufacturing facility in Dammam, Saudi Arabia. The second-phase expansion doubles ITT's manufacturing capacity, with a third phase expected to begin in 2027, the company said. In 2024, the Dammam facility received $160...
Copyright 2023-2026 - www.financetom.com All Rights Reserved